Oxazolidinones: a novel class of antibiotics
Oxazolidinones are a novel class of synthetic antimicrobial agents which have now entered phase III clinical trials. The most promising feature of these compounds is their oral activity against multidrug-resistant Gram-positive bacteria which have created tremendous therapeutic problems in recent ye...
Gespeichert in:
| Veröffentlicht in: | Cellular and molecular life sciences : CMLS 1999-10, Vol.56 (3-4), p.280-285 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 285 |
|---|---|
| container_issue | 3-4 |
| container_start_page | 280 |
| container_title | Cellular and molecular life sciences : CMLS |
| container_volume | 56 |
| creator | Müller, M Schimz, K L |
| description | Oxazolidinones are a novel class of synthetic antimicrobial agents which have now entered phase III clinical trials. The most promising feature of these compounds is their oral activity against multidrug-resistant Gram-positive bacteria which have created tremendous therapeutic problems in recent years. In addition, development of resistance in vitro has so far remained below detectable levels. Different from many antibacterial agents used in the treatment of human infections, oxazolidinones do not block bacterial protein synthesis at the level of polypeptide chain elongation but rather seem to interfere with initiation of translation. Both binding of formylmethionine-transfer RNA to initiation complexes as well as release of formylmethioninepuromycin from initiation complexes have been reported to be targets for oxazolidinones. The major binding sites of oxazolidinones are the large (50S) ribosomal subunits. |
| doi_str_mv | 10.1007/s000180050429 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11149551</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69505998</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-814109cd83bd8c1d020951b78b48c8c286b4a1b1f243f5e4698233fe1a7487bf3</originalsourceid><addsrcrecordid>eNpdkc1Lw0AQxRdRbP04epXgwZPRmf1Idr2IFL-g0IuCt2Wz2eiWNFuzaVH_eiMtaj3NwPx4vHmPkCOEcwTILyIAoAQQwKnaIkPkFFIFOW6v90zS5wHZi3Hag0LSbJcMEClSJsSQnE3ezWeofemb0Lh4mZikCUtXJ7Y2MSahSkzT-cKHztt4QHYqU0d3uJ775On25nF0n44ndw-j63FqWU67VCJHULaUrCilxRIoKIFFLgsurbRUZgU3WGBFOauE45mSlLHKocm5zIuK7ZOrle58UcxcaV3TtabW89bPTPuhg_F689L4V_0SlhoRuRICe4XTtUIb3hYudnrmo3V1bRoXFlFnSoBQSvbgyT9wGhZt03-npWK5AGR5D6UryLYhxtZVP1YQ9HcLeqOFnj_-6_-XXsfOvgArlIC7</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>893750137</pqid></control><display><type>article</type><title>Oxazolidinones: a novel class of antibiotics</title><source>MEDLINE</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Müller, M ; Schimz, K L</creator><creatorcontrib>Müller, M ; Schimz, K L</creatorcontrib><description>Oxazolidinones are a novel class of synthetic antimicrobial agents which have now entered phase III clinical trials. The most promising feature of these compounds is their oral activity against multidrug-resistant Gram-positive bacteria which have created tremendous therapeutic problems in recent years. In addition, development of resistance in vitro has so far remained below detectable levels. Different from many antibacterial agents used in the treatment of human infections, oxazolidinones do not block bacterial protein synthesis at the level of polypeptide chain elongation but rather seem to interfere with initiation of translation. Both binding of formylmethionine-transfer RNA to initiation complexes as well as release of formylmethioninepuromycin from initiation complexes have been reported to be targets for oxazolidinones. The major binding sites of oxazolidinones are the large (50S) ribosomal subunits.</description><identifier>ISSN: 1420-682X</identifier><identifier>EISSN: 1420-9071</identifier><identifier>DOI: 10.1007/s000180050429</identifier><identifier>PMID: 11212355</identifier><language>eng</language><publisher>Switzerland: Springer Nature B.V</publisher><subject>Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Antibacterial agents ; Antibiotics ; Antimicrobial agents ; Bacteria ; Bacterial proteins ; Drug Resistance, Microbial ; Drug Resistance, Multiple ; Gram-positive bacteria ; Gram-Positive Bacteria - drug effects ; Gram-Positive Bacterial Infections - drug therapy ; Humans ; Oxazolidinones - pharmacology ; Oxazolidinones - therapeutic use ; Pharmacology ; Protein synthesis ; Transfer RNA</subject><ispartof>Cellular and molecular life sciences : CMLS, 1999-10, Vol.56 (3-4), p.280-285</ispartof><rights>Birkhäuser Verlag Basel, 1999</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-814109cd83bd8c1d020951b78b48c8c286b4a1b1f243f5e4698233fe1a7487bf3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149551/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149551/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11212355$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Müller, M</creatorcontrib><creatorcontrib>Schimz, K L</creatorcontrib><title>Oxazolidinones: a novel class of antibiotics</title><title>Cellular and molecular life sciences : CMLS</title><addtitle>Cell Mol Life Sci</addtitle><description>Oxazolidinones are a novel class of synthetic antimicrobial agents which have now entered phase III clinical trials. The most promising feature of these compounds is their oral activity against multidrug-resistant Gram-positive bacteria which have created tremendous therapeutic problems in recent years. In addition, development of resistance in vitro has so far remained below detectable levels. Different from many antibacterial agents used in the treatment of human infections, oxazolidinones do not block bacterial protein synthesis at the level of polypeptide chain elongation but rather seem to interfere with initiation of translation. Both binding of formylmethionine-transfer RNA to initiation complexes as well as release of formylmethioninepuromycin from initiation complexes have been reported to be targets for oxazolidinones. The major binding sites of oxazolidinones are the large (50S) ribosomal subunits.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Bacteria</subject><subject>Bacterial proteins</subject><subject>Drug Resistance, Microbial</subject><subject>Drug Resistance, Multiple</subject><subject>Gram-positive bacteria</subject><subject>Gram-Positive Bacteria - drug effects</subject><subject>Gram-Positive Bacterial Infections - drug therapy</subject><subject>Humans</subject><subject>Oxazolidinones - pharmacology</subject><subject>Oxazolidinones - therapeutic use</subject><subject>Pharmacology</subject><subject>Protein synthesis</subject><subject>Transfer RNA</subject><issn>1420-682X</issn><issn>1420-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkc1Lw0AQxRdRbP04epXgwZPRmf1Idr2IFL-g0IuCt2Wz2eiWNFuzaVH_eiMtaj3NwPx4vHmPkCOEcwTILyIAoAQQwKnaIkPkFFIFOW6v90zS5wHZi3Hag0LSbJcMEClSJsSQnE3ezWeofemb0Lh4mZikCUtXJ7Y2MSahSkzT-cKHztt4QHYqU0d3uJ775On25nF0n44ndw-j63FqWU67VCJHULaUrCilxRIoKIFFLgsurbRUZgU3WGBFOauE45mSlLHKocm5zIuK7ZOrle58UcxcaV3TtabW89bPTPuhg_F689L4V_0SlhoRuRICe4XTtUIb3hYudnrmo3V1bRoXFlFnSoBQSvbgyT9wGhZt03-npWK5AGR5D6UryLYhxtZVP1YQ9HcLeqOFnj_-6_-XXsfOvgArlIC7</recordid><startdate>19991015</startdate><enddate>19991015</enddate><creator>Müller, M</creator><creator>Schimz, K L</creator><general>Springer Nature B.V</general><general>Birkhäuser Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7SS</scope><scope>7T5</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PATMY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PYCSY</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19991015</creationdate><title>Oxazolidinones: a novel class of antibiotics</title><author>Müller, M ; Schimz, K L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-814109cd83bd8c1d020951b78b48c8c286b4a1b1f243f5e4698233fe1a7487bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Bacteria</topic><topic>Bacterial proteins</topic><topic>Drug Resistance, Microbial</topic><topic>Drug Resistance, Multiple</topic><topic>Gram-positive bacteria</topic><topic>Gram-Positive Bacteria - drug effects</topic><topic>Gram-Positive Bacterial Infections - drug therapy</topic><topic>Humans</topic><topic>Oxazolidinones - pharmacology</topic><topic>Oxazolidinones - therapeutic use</topic><topic>Pharmacology</topic><topic>Protein synthesis</topic><topic>Transfer RNA</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Müller, M</creatorcontrib><creatorcontrib>Schimz, K L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Environmental Science Collection</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cellular and molecular life sciences : CMLS</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Müller, M</au><au>Schimz, K L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oxazolidinones: a novel class of antibiotics</atitle><jtitle>Cellular and molecular life sciences : CMLS</jtitle><addtitle>Cell Mol Life Sci</addtitle><date>1999-10-15</date><risdate>1999</risdate><volume>56</volume><issue>3-4</issue><spage>280</spage><epage>285</epage><pages>280-285</pages><issn>1420-682X</issn><eissn>1420-9071</eissn><abstract>Oxazolidinones are a novel class of synthetic antimicrobial agents which have now entered phase III clinical trials. The most promising feature of these compounds is their oral activity against multidrug-resistant Gram-positive bacteria which have created tremendous therapeutic problems in recent years. In addition, development of resistance in vitro has so far remained below detectable levels. Different from many antibacterial agents used in the treatment of human infections, oxazolidinones do not block bacterial protein synthesis at the level of polypeptide chain elongation but rather seem to interfere with initiation of translation. Both binding of formylmethionine-transfer RNA to initiation complexes as well as release of formylmethioninepuromycin from initiation complexes have been reported to be targets for oxazolidinones. The major binding sites of oxazolidinones are the large (50S) ribosomal subunits.</abstract><cop>Switzerland</cop><pub>Springer Nature B.V</pub><pmid>11212355</pmid><doi>10.1007/s000180050429</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1420-682X |
| ispartof | Cellular and molecular life sciences : CMLS, 1999-10, Vol.56 (3-4), p.280-285 |
| issn | 1420-682X 1420-9071 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11149551 |
| source | MEDLINE; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Antibacterial agents Antibiotics Antimicrobial agents Bacteria Bacterial proteins Drug Resistance, Microbial Drug Resistance, Multiple Gram-positive bacteria Gram-Positive Bacteria - drug effects Gram-Positive Bacterial Infections - drug therapy Humans Oxazolidinones - pharmacology Oxazolidinones - therapeutic use Pharmacology Protein synthesis Transfer RNA |
| title | Oxazolidinones: a novel class of antibiotics |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A51%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oxazolidinones:%20a%20novel%20class%20of%20antibiotics&rft.jtitle=Cellular%20and%20molecular%20life%20sciences%20:%20CMLS&rft.au=M%C3%BCller,%20M&rft.date=1999-10-15&rft.volume=56&rft.issue=3-4&rft.spage=280&rft.epage=285&rft.pages=280-285&rft.issn=1420-682X&rft.eissn=1420-9071&rft_id=info:doi/10.1007/s000180050429&rft_dat=%3Cproquest_pubme%3E69505998%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=893750137&rft_id=info:pmid/11212355&rfr_iscdi=true |